StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report sent to investors on Saturday. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Up 250.3 %

Shares of NASDAQ:ADXS opened at $0.11 on Friday. The stock has a market cap of $4.48 million, a price-to-earnings ratio of -0.01 and a beta of 1.63. Ayala Pharmaceuticals has a 12-month low of $0.00 and a 12-month high of $0.97. The business’s 50 day moving average is $0.03 and its 200 day moving average is $0.03.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.